All In Biotech

NDA 207946 · Janssen Pharms

Invega Hafyera

Paliperidone Palmitate · Intramuscular

Priority review

Last checked: Nov 20, 2026Latest source record: Jan 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

May 18, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

144

50 Phase 3, 2 recruiting

FAERS reports

8,538

5,139 serious, 599 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA HAFYERA is not approved for use in patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA HAFYERA is not approved for use in patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Feb 18, 2025.

INVEGA HAFYERA, an every-six-month injection, is indicated for the treatment of schizophrenia in adults after they have been adequately treated with: A once-a-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA SUSTENNA) for at least four months, or An every-three-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA TRINZA) for at least one three-month cycle. INVEGA HAFYERA, an every-six-month injection, is an atypical antipsychotic indicated for the treatment of schizophrenia in adults after they have been adequately treated with: A once-a-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA SUSTENNA) for at least four months or An every-three-month paliperidone palmitate extended-release injectable suspension (e.g., INVEGA TRINZA) for at least one three-month cycle. ( 1 )

Mechanism: Paliperidone palmitate is hydrolyzed to paliperidone [see Clinical Pharmacology (12.3) ] . Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unclear. However, its efficacy in the treatment of schizophrenia could be mediated through a combination of central dopamine D 2 and serotonin 5HT 2A receptor antagonism.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • INVEGA HAFYERA · PALIPERIDONE PALMITATE 1.560GM/5ML (312MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • INVEGA TRINZA · PALIPERIDONE PALMITATE 819MG/2.625ML (312MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • INVEGA TRINZA · PALIPERIDONE PALMITATE 410MG/1.315ML (311.79MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • INVEGA HAFYERA · PALIPERIDONE PALMITATE 1.092GM/3.5ML (312MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • INVEGA TRINZA · PALIPERIDONE PALMITATE 546MG/1.75ML (312MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • INVEGA TRINZA · PALIPERIDONE PALMITATE 273MG/0.875ML (273MG/0.875ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Paliperidone Palmitate" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective842
  • off label use790
  • hospitalisation646
  • schizophrenia556
  • condition aggravated508
  • product dose omission issue407
  • therapeutic response decreased342
  • death319
  • psychotic disorder317
  • weight increased307
  • suicide attempt264
  • dyskinesia260

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
20071
20081
20095
20107
201115
201276
201374
201449
2015126
2016445
2017769
2018609
2019609
2020504
2021592
20221,262
20231,107
2024962
2025786
2026537

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Invega Hafyera (Paliperidone Palmitate)

2024 spending

$109M

Beneficiaries

3,448

5,856 claims

Per beneficiary

$31,737

$4,143.61 per unit

View as table
YearSpending
2020$0
2021$2,953,004
2022$40,918,618
2023$79,118,112
2024$109,428,680

Part D: Invega Trinza (Paliperidone Palmitate)

2024 spending

$550M

Beneficiaries

19,150

63,911 claims

Per beneficiary

$28,710

$3,985.21 per unit

View as table
YearSpending
2020$416,510,098
2021$438,928,871
2022$476,700,024
2023$529,817,416
2024$549,801,574

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 135 on PubMed

Sponsor: Johnson & Johnson (Janssen) · Also marketed as Invega Trinza

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.